InSysBio to participate in Quantitative Systems Pharmacology for Immuno-Oncology

April 4, 2022

April 4, 2022

InSysBio announces its participation in Quantitative Systems Pharmacology for Immuno-Oncology, a joint meeting of the EMBL's European Bioinformatics Institute (EMBL-EBI) & the UK QSP Network which is to be held 25th & 26th April 2022 in person at the EMBL-EBI Main Building, Wellcome Genome Campus, Hinxton, Cambridgeshire, UK, and online via Zoom. 

Oleg Demin Jr, InSysBio Scientific & Marketing Director, Oncology & Immuno-Oncology, will give a talk in frames of Theme 1: Combination Therapy.

Monday, April 25, 11:20-11:45

  • "Specific aspects of the implementation of different combination therapies in the QSP model"

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit